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Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects
of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may
be linked to Parkinson-like events and dementia, or variants of these diseases. Two recent
case reports have found a potential link between intravitreal anti-VEGF use and
Parkinson’s disease (PD) and dementia.
Aim: To evaluate disproportionality in a large spontaneous reporting database concerning
intravitreal anti-VEGF drugs and PD or dementia, and related conditions.
Methods: Using VigiBase, individual case safety reports (ICSRs) attributed to intravitreal
ranibizumab, aflibercept, pegaptanib, and bevacizumab were identified from 2010 to
2016. Within Standardised Narrow Medical Dictionary for Regulatory Activities
(MedDRA®) Queries (SMQs) for “Parkinson-like events” and “Dementia,” suspected
events were identified using preferred terms (PTs). The Proportional Reporting Ratio
(PRR) was estimated with the lower 95% confidence intervals (CIs) for all drug-event pairs
with ≥3 suspected events. The vigiGrade completeness score was reported for the
ICSRs. The analyses were repeated, including only persons aged 65 and over.
Results: Out of 18.9 million ICSRs, 7,945 (0.004%) concerned intravitreal anti-VEGF
drugs. Of these, 27 (0.34%) were identified concerning the SMQs “Dementia” (N = 17,
62.96%) and “Parkinson-like events” (N = 10, 37.94%) in persons of all ages. Among
persons age 65 and over, 4,758 (59.88% of relevant ICSRs) ICSRs were identified for anti-
VEGF drugs. When restricting disproportionality analysis to persons aged 65 and over, no
disproportionality was seen for any of the drug-event pairs at the level of SMQ. However,
on analysing disproportionality by PT, a potential signal emerged for intravitreal
ranibizumab and Parkinson’s disease [N = 6 ICSRs; PRR: 3.05 (95% CI: 1.36-6.81)]. In
general, the vigiGrade completeness score was low for all the ICSRs of interest, as no
ICSR had a score >0.8.in.org March 2020 | Volume 11 | Article 3151
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Frontiers in Pharmacology | www.frontiersConclusion: Present findings suggest a potential signal for Parkinson’s disease related to
intravitreal ranibizumab. This is supported by several biologically plausible mechanisms
but requires confirmation through pharmacoepidemiological studies, especially because
of the low number of cases.Keywords: pharmacovigilance, VigiBase, Alzheimer’s disease, Parkinson’ disease, dementia, neurodegeneration,
antivascular endothelial growth factor drugs, intravitrealHIGHLIGHTS
• Although the ophthalmological safety profile of intravitreal
anti-VEGF drugs has been described in detail, their systemic
safety, including the risk of neurodegenerative diseases, is still
coming to light.
• Among 7,945 case reports, of which 4,758 (59.9%) concerned
persons aged 65 and over, for intravitreal ranibizumab,
aflibercept, pegaptanib, or bevacizumab in VigiBase from
2010–2016, we identified nine potential cases of dementia
and eight potential cases of Parkinson-like events.
• A potential signal concerning Parkinson’s disease was
identified in relation to intravitreal ranibizumab use.INTRODUCTION
Vascular endothelial growth factor (VEGF) plays an important
role in regulating physiological angiogenesis (Ferrara et al.,
2003), inducing vascular permeability and promoting the
survival of newly formed blood vessels (McColl et al., 2004).
To date, six different VEGF isoforms have been identified
(Robinson and Stringer, 2001). Retinal vascular diseases, such
as age-related macular degeneration (AMD), diabetic macular
oedema (DME), retinal vein occlusion (RVO), and choroidal
neovascularization in myopic patients (mCNV), are the most
common causes of vision loss in developed countries (Wong
et al., 2014). Retinal hypoxia is the driver of these diseases,
leading to elevated levels of hypoxia-inducible factor-1 (HIF-1),
which in turn stimulates over-expression of VEGF
(Campochiaro, 2013). The inhibition of VEGF is therefore a
key pharmacological objective in these diseases (Ferrara, 2002).
Three anti-VEGF drugs, ranibizumab, aflibercept and
pegaptanib, are currently marketed in Europe and North America
for the intravitreal treatment of the above-mentioned retinal
diseases, while bevacizumab is commonly used off-label for retinal
vascular diseases, as its main indication is oncological. Although
these anti-VEGF drugs are injected locally, they can lead to a large
reduction in systemic plasma free-VEGF levels; a prospective
clinical study found that a subset of patients were found to have a
significant reduction in VEGF levels over three monthly intravitreal
anti-VEGF administrations, persisting up to one month after
treatment (Avery et al., 2017). The marked systemic suppression
of VEGF may have implications for the systemic safety of anti-
VEGF drugs. Indeed, a meta-analysis of randomized clinical trialsin.org 2(RCTs) on systemic adverse events showed that intravitreal anti-
VEGF drugs, specifically ranibizumab, were associated with an
increased risk of non-ocular haemorrhage (Thulliez et al., 2018).
Findings by Thulliez et al. were in line with findings of a previous
meta-analysis of RCTs, suggesting that long-term intravitreal
ranibizumab users were at risk of systemic vascular adverse events
(Ueta et al., 2014). Both meta-analyses suggested that the systemic
ADRs investigated in clinical trials were more likely to occur in
patients with AMD. The many limitations of RCTs in capturing
ADRs (Sultana et al., 2013) highlight the importance of confirming
such safety issues using real-world studies. An Italian nationwide
pharmacovigilance study confirmed the plausibility of intravitreal
anti-VEGF drugs being associated with systemic ADRs, including
arterial thromboembolic events, such as stroke and myocardial
infarction (Cutroneo et al., 2017). In addition to these ADRs, it
has recently come to light that anti-VEGF drugs could be a risk
factor for neurodegenerative processes.
Two recent case reports concerning intravitreal anti-VEGF
use, one from Italy (Trifirò et al., 2018) and one from Germany
(Meyer et al., 2018), identified a potential link with Parkinson’s
disease and cognitive impairment, respectively. The former case
report suggests a link between repeated intravitreal use of
ranibizumab and Parkinsonism in an elderly patient with wet
AMD (Trifirò et al., 2018). The other case report describes
anterograde amnesia and confusion occurring with repeated
intravitreal administration of ranibizumab followed by
bevacizumab (Meyer et al., 2018). Indeed, an in vitro study
examined the effect of VEGF on cellular processes or factors
that modulate neuron survival (e.g., expression of proteins
favoring or attenuating apoptotic processes and release of
neurotrophic or neurotoxic factors), as well as on neuron
survival directly. This study found that VEGF improved
neuron survival in a dose-dependent manner; this correlated
with a reduction in apoptosis-inducing proteins, an increase in
apoptosis-preventing proteins and neurotrophic factors such as
pigment epithelial-derived factor and a reduction in amyloid
beta, which is the neurotoxic protein involved in Alzheimer’s
disease (Sanchez et al., 2010).
Except for these case studies and one in vitro experimental
study, the evidence on the potential link between anti-VEGF
drugs and neurodegeneration is poor. The aim of the present
study was therefore to investigate the potential association
between the use of intravitreal anti-VEGF drugs and dementia
and Parkinson-related disorders using VigiBase, the World
Health Organization (WHO) international spontaneous
reporting database, by calculating Proportional Reporting
Ratios as a disproportionality measure.March 2020 | Volume 11 | Article 315
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Data Source
VigiBase, the WHO global database of individual case safety
reports (ICSRs), was used as a data source. VigiBase is the largest
spontaneous ADR report database worldwide, founded in 1968
by the WHO Programme for International Drug Monitoring,
managed by the Uppsala Monitoring Centre (UMC). VigiBase
contains anonymised information on suspected ADR reports
associating one or more medicinal products to one or more
suspected ADRs. It currently contains over 20 million reports
collected globally. This database has been described in detail
elsewhere (Lindquist, 2008). Data for the present study was
obtained from 2010–2016.
Study Drugs
For the present study, only ICSRs attributed to intravitreal anti-
VEGF drugs, whether with licensed ophthalmologic indications
or off-label, were identified and selected. During the study
period, the following drugs were available on market and
were there fore inc luded in the study : afl ibercept ,
ranibizumab, bevacizumab, and pegaptanib. In addition, the
intravitreal implant of the corticosteroid dexamethasone was
also considered as a separate exposure of interest, as this has a
major overlapping indication of use (DME) with intravitreal
anti-VEGF drugs and a similar route of administration. ICSRs
where route of drug administration was not specifically
reported were excluded. All study drugs were identified by
generic name.
Suspected Events
The present study focused on two neurodegenerative diseases
and related symptoms, i.e., Parkinson-like events and dementia.
Suspected events were first identified using Standardised Narrow
Medical Dictionary for Regulatory Activities (MedDRA®)
Queries (SMQs) for “Parkinson-like events” and “Dementia”
(Online Resource, Table 1). SMQs are composed of preferred
terms (PTs) that refer to a range of clinical concepts, including
syndromes, well-defined diseases and symptoms. A single ICSR
may have more than one SMQ and/or more than one PT per
each SMQ. As a result, the number of PTs does not alwaysFrontiers in Pharmacology | www.frontiersin.org 3correspond to the same number of SMQs. The diversity of
concepts between SMQs and PTs gave rise to potential
conceptual overlap which is inherent to the MedDRA®
classification system. In addition, PTs that fall under an SMQ
do not all necessarily have the same level of clinical detail, as
some refer to diseases while others to symptoms. A hierarchical
concept map was created to provide an overview of the level of
conceptual clinical detail encompassed by all the SMQs and PTs
considered in the present study (Online Resource, Figure 1). We




To detect potential safety signals, the main method of
disproportionality analysis used was the Proportional
Reporting Ratio (PRR), along with lower 95% confidence
intervals (95% CI). PRR is a widely used measure of
association applied to spontaneous reports databases (Evans
et al., 2001). The PRR was calculated using as comparison
group all other reports for any drugs administered by any
route in VigiBase from 2010–2016, first in persons of all ages
then restricting only to persons aged 65 and over. This restriction
was carried out in order to reduce confounding due to age
because dementia and Parkinson-like events are more frequent
in elderly persons compared to younger ones. For a signal to
emerge in this population of elderly persons, the events of
interest have to be more common than the background
reporting of these events among elderly persons. PRR was only
calculated where three or more events of interest were identified.
Where the PRR was significant, the following information was
extracted from the original ICSRs, where available: sex, age at
reporting date, indication of drug use, time to suspected event
onset (i.e., time elapsed between the date of drug initiation and
the date of event reported) and causality assessment. Information
on dose was not collected, as there as is only one strength
available for each drug. Furthermore, only where the PRR was
significant, two other measures of disproportionality were
calculated to confirm the results: the reporting odds ratio
(ROR) and information component (IC). ROR was presented
with 95% CI while IC was presented with IC025, i.e., the lower endTABLE 1 | Individual case safety reports concerning intravitreal antivascular endothelial growth factor or dexamethasone implant use, grouped by standardized
MedDRA® query, in patients of all ages.
Intravitreal drug SMQ N PRR (95% CI)
Aflibercept Dementia 6 2.78 (1.25–6.21)
Parkinson-like events 3 0.65 (0.21–2.02)
Ranibizumab Dementia 11 2.50 (1.38–4.52)
Parkinson-like events 6 0.64 (0.28–1.42)
Pegaptanib Dementia – –
Parkinson-like events – –
Bevacizumab Dementia – –
Parkinson-like events 1 NA
Dexamethasone Dementia – –
Parkinson-like events – –March 2020 | VolumeSignals of disproportionate reporting are highlighted in bold where statistical significance is reached and more than three cases were identified. N, number; NA, not assessable;
CI, confidence interval; PRR, Proportional Reporting Ratio; SMQ, standardized MedDRA® queries.11 | Article 315
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clustering ICSRs first by SMQ and separately, by PT.
The causality assessment was carried out for each report
where the PRR was significant, using the WHO-UMC system for
standardised case causality assessment, resulting in the following
likelihood of causality being assigned: certain, probable/likely,
possible, unlikely, conditional/unclassified, and unassessable/
unclassifiable. The vigiGrade completeness score, developed by
the UMC, was used to measure the completeness of the ICSRs.
This score takes into account the completeness of the following
fields: time-to-onset, age, sex, indication, outcome, report type,
dose, country, primary reporter, and comments. The best score
possible is 1 but scores >0.8 are nevertheless considered to denote
a good level of completeness (Bergvall et al., 2014).
Further analyses were conducted where the PRR was
significant, such as stratification of results by age (65–74 years
and ≥75 years) and by sex.
Ethics Approval and Data Protection
The present study did not require ethics approval as it was
conducted using retrospectively collected, de-identified data.
Descriptive patient-level tables containing information (e.g., sex,
age, country of origin, and indication of drug use) on 10 patients or
less were not presented to further protect patient privacy.RESULT
Signal Detection
During the study period, there were over 18.9 million ICSRs in
VigiBase of which 7,945 (0.004%) ICSRs concerned intravitreal
anti-VEGF drugs and any suspected event among persons of allFrontiers in Pharmacology | www.frontiersin.org 4ages. From this pool of ICSRs for intravitreal anti-VEGF drugs,
27 (0.33%) were identified concerning the narrow SMQs for
“Parkinson-like events” and “Dementia” which were potentially
related to intravitreal anti-VEGF drugs. No reports were found
concerning dexamethasone intravitreal implant and the events in
question. Concerning intravitreal anti-VEGF drugs, 10 ICSRs for
the SMQ “Parkinson-like events” and 17 ICSRs for the SMQ
“Dementia” were identified for persons of all ages. The
disproportionality analysis carried out at level of the SMQs
suggested a statistically significant PRR for intravitreal
ranibizumab use in relation to “Dementia” 2.50 (95% CI: 1.38–
4.52), with N = 11 ICSRs. Similarly, a significant PRR was
observed for aflibercept in relation to the SMQ “Dementia”
[PRR: 2.78 (95% CI: 1.25–6.21)], with N = 6 ICSRs. No
statistically significant signal of disproportionality was found
for any of the anti-VEGF drugs included in the study and the
SMQ “Parkinson-like events” (Table 1). On increasing the
specificity of the suspected events by conducting analyses at
the level of PT, a trend of disproportionality among persons of all
ages emerged for one intravitreal anti-VEGF drug and
“Parkinson’s disease”, specifically ranibizumab, with a PRR of
3.11 (95% CI: 1.39–6.94) concerning N=6 ICSRs. The
disproportionality analysis among PTs making up the narrow
SMQ “Dementia” yielded a potential signal for ranibizumab and
the PT “Dementia, Alzheimer type” [N = 5, with a PRR of 4.55
(95% CI: 1.89–11.0)] (Table 2). Disproportionality was also
identified for intravitreal aflibercept and the PT “Dementia”
[N = 5, PRR: 3.37 (95% CI: 1.40–8.14)].
Among elderly persons, a total of 4,758 (59.9% of all anti-VEGF
related reports) ICSRs were identified, eight (0.2%) concerning the
SMQ “Dementia” and nine (0.2%) ICSRs for the SMQ “Parkinson-
like events.”Whenrestrictingdisproportionality analysis topersonsFIGURE 1 | Possible mechanisms of action by which intravitreal antivascular endothelial growth factor drugs could increase the risk of neurodegenerative disease
such as Parkinson’s disease and Alzheimer’s disease. ROS, reactive oxygen species; PEDF, pigment epithelium-derived factor; VEGF, vascular endothelial growth
factor. (Sanchez et al., 2010; De Rossi et al., 2016; Caballero et al., 2017).March 2020 | Volume 11 | Article 315
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drug-event pairs at the level of SMQ (Table 3). However, on
analysing disproportionality by PT, a potential signal emerged for
ranibizumab andParkinson’s disease [N= 6 ICSRs; PRR: 3.05 (95%
CI: 1.36–6.81)] (Table 4).
A non-significant trend of disproportionality concerning
dementia was seen both at the level of SMQ [1.36 (95% CI:
0.68-2.72)] and at the level of PT [1.24 (95% CI: 0.51–3.00)] in
relation to intravitreal ranibizumab use. When the ICSRs for the
ranibizumab-Parkinson’s disease PT were stratified by age group
(65–74 and >74) and sex, a trend of disproportionality was seen
for PRR and ROR while the IC suggested a very weak, borderline
disproportionality for persons aged 65 to 74. It was very difficult
to interpret these results reliably due to the small number of
ICSRs (Online Resource, Table 2).
Case Description for Safety Signals
The patient-level case description for the six ICSRs was not
presented in tabular format to protect patients’ privacy. Within
the SMQ “Parkinson-like events”, six ICSRs were identified for theFrontiers in Pharmacology | www.frontiersin.org 5PT “Parkinson’s disease” in relation to intravitreal ranibizumab.
The mean age for patients developing “Parkinson’s disease” after
exposure to ranibizumabwas 76.5 ± 5.6; age was not missing any of
these ICSRs. Overall, for the PT “Parkinson’s disease,” 83% of
persons exposed to ranibizumab in the ICSRs were males; no
missing gender information was identified for this drug-event
pair. The mean time to onset was estimable for four out of six
ICSRs, and was 2.3 ± 2.0 years. For the six ICSRs containing the PT
“Parkinson’s disease,” the causality assessment for ranibizumabwas
“possible” for five (83.33%) ICSRs and “unlikely” for one (16.66%)
ICSR. Causality was always assessable for this PT. In general, the
vigiGrade completeness score was low for all the ICSRs of interest,
as not a single ICSR had a score >0.8. The median (1st–3rd quartile)
value was 0.58 (0.30–0.71).DISCUSSION
The main finding from this study was the identification of a
potential signal related to the occurrence of Parkinson’s diseaseTABLE 4 | Individual case safety reports for intravitreal ranibizumab grouped by preferred term, in patients aged 65 years or older.
PT Drug N PRR (95% CI)
Parkinson’s disease Ranibizumab 6 3.05 (1.36–6.81)
Aflibercept 1 NA
Hypertonia Ranibizumab 2 NA
Akinesia Aflibercept 1 NA
Dementia Ranibizumab 5 1.24 (0.51–3.00)
Aflibercept 1 NA
Mixed dementia Ranibizumab 1 NAMarch 2020 | VolumeSignals of disproportionate reporting are highlighted in bold where statistical significance is reached and more than three cases were identified. CI, confidence interval; N, number; NA, not
assessable; PT, preferred term; PRR, Proportional Reporting Ratio.TABLE 2 | Individual case safety reports for intravitreal ranibizumab, aflibercept, and bevacizumab grouped by preferred term related to dementia and/or Parkinson-like
events standardized MedDRA queries, in patients of all ages.
SMQ Intravitreal drug PT N PRR (95% CI)
Dementia Aflibercept Dementia 5 3.37 (1.40–8.14)
Senile dementia 1 NA
Ranibizumab Dementia, Alzheimer’s type 5 4.55 (1.89–11.0)
Mixed Dementia 1 NA
Dementia 6 1.98 (0.89–4.42)
Parkinson-like events Aflibercept Akinesia 1 NA
Parkinson’s disease 2 NA
Ranibizumab Hypertonia 2 NA
Parkinson’s disease 6 3.11 (1.39–6.94)Signals of disproportionate reporting are highlighted in bold where statistical significance is reached and more than three cases were identified. CI, confidence interval; N, number; NA, not
assessable; PT, preferred term; PRR, Proportional Reporting Ratio; SMQ, standardized MedDRA® queries.TABLE 3 | Individual case safety reports for intravitreal ranibizumab and aflibercept in persons aged 65 and over, grouped by standardized MedDRA® query related to
dementia and/or Parkinson-like events standardized MedDRA queries.
SMQ Intravitreal drug N PRR (95% CI)
Dementia Aflibercept 1 –
Ranibizumab 8 1.36 (0.68–2.72)
Parkinson-like events Aflibercept 2 NA
Ranibizumab 6 0.85 (0.38–1.89)CI, confidence interval; N, number; PRR, Proportional Reporting Ratio; SMQ, standardized MedDRA® queries.11 | Article 315
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evaluate the occurrence of this signal. The reason why
disproportionality was significant only concerning ranibizumab is
very unlikely to be explained exclusively by its mechanism of action,
which is almost identical to other anti-VEGF drugs (Avery et al.,
2017). A more likely explanation is the low statistical power
achieved in the study. Furthermore, intravitreal ranibizumab has
been on the market longer than other drugs, such as aflibercept, and
it is more commonly used than pegaptanib, which has fewer
ophthalmologic indications than ranibizumab. As a result, it is
possible that the number of persons exposed to ranibizumab is
much higher than other anti-VEGF drugs. The reason why
disproportionality was not seen for dementia may be related to
the high background reporting rate of this event in elderly persons
as well as the low number of cases identified. Nevertheless, a trend
suggesting non-significant disproportionality was identified for
intravitreal ranibizumab and dementia among elderly persons.
The neurological symptoms of the potentially intravitreal
anti-VEGF induced Parkinsonism outlined in a case report a
few years ago were described in great detail, suggesting that
this kind of Parkinsonism may present with atypical features,
such lack of cortical and subcortical atrophy (Trifirò et al.,
2018). The authors of this case report note that idiopathic PD
cannot be excluded, since several neurologic features are
consistent with this diagnosis, including vascular lesions in
the basal ganglia and DAT SPECT results showing pre-
synaptic dopamine loss. On the other hand, the case report
concerning the occurrence of amnesia with intravitreal
bevacizumab and ranibizumab use did not provide such a
high level of neurological detail as the case report by Trifirò
et al. and as a result, it is difficult to understand whether the
pathophysiological context is consistent with amnesia
occurring to due neurodegenerative processes (Meyer et al.,
2018). Meyer et al. report that the patient complained of mild
memory impairment prior to treatment with anti-VEGF
drugs, with a cranial MRI of the patient suggesting
moderate brain atrophy prior to intravitreal anti-VEGF use.
However a mini-mental state exam (MMSE) indicated almost
intact cognitive function (29 points out of 30). It is therefore
unlikely that pre-existing cognitive impairment explains the
acute confusional state which developed after intravitreal
anti-VEGF use. Meyer et al. report that on discontinuing
intravitreal anti-VEGF treatment, no further amnesia
developed and that cranial MRI two years after the first
intravitreal anti-VEGF exposure did not show any
significant differences compared to before treatment,
presumably in terms of atrophy (a detailed description of
the results was not available). From this case report, the
plausibility of anti-VEGF drugs as a risk factor for dementia
in a neurodegenerative context, i.e. a progressive and long-
term symptom, is not clear and requires further elucidation.
The plausibility of the association between intravitreal
anti-VEGF drugs and neurodegenerative diseases such as
Parkinson’s disease is supported by a large body of pre-
clinical evidence. Firstly, there are several biologically
plausible mechanisms by which the study drugs could haveFrontiers in Pharmacology | www.frontiersin.org 6led to or contributed to neuropathological processes common
t o bo t h P a r k i n s o n ’ s d i s e a s e a nd and t o o t h e r
neurodegenerative diseases (Figure 1). The inhibition of
VEGF is known to lead to a reduction in synaptic function
and plasticity, leading to impaired neuron signalling (Sharma
et al., 2019). Furthermore, inhibition of VEGF can lead to a
reduction in Bcl-2 gene expression and increase in the protein
caspase-3, with both these two effects leading to increased cell
death (Sanchez et al., 2010). Antagonism of VEGF receptors
has also been linked to an increase in free-radical oxygen
species with resulting damage to mitochondria (De Rossi
et al., 2016) as well as stimulating the release of b-amyloid,
a protein which is the hallmark of Alzheimer’s disease and can
co-occur in Parkinson’s disease (Sanchez et al., 2010; Lim
et al., 2019). Although one of the dementia-related PTs in the
signals identified did not specifically refer to Alzheimer’s
disease, this particular type of dementia is the most frequent
subtype, known to account for 60-80% of all dementia cases
(Caballero et al., 2017). We therefore expect that the majority
of identified non-specific dementia events will likely refer to
Alzheimer’s disease.
Concerning the risk of Parkinson’s disease, it is known that
VEGF administration inhibits loss of dopaminergic neurons in
experimental models, particularly in the substantia nigra and in
the striatum (Kumar and Tsao, 2018). A reduction in plasma
free-VEGF levels also leads to a reduction in pigment
epithelium-derived factor (PEDF), a neuroprotective protein
that promotes cell survival (Sanchez et al., 2010). In addition,
low VEGF levels may impair neural tissue perfusion, causing
ischaemia and production of free radicals (Sheikh et al., 2017).
VEGF is known to be neuroprotective, inhibiting apoptosis,
stimulating neurogenesis and activating antioxidants
(Storkebaum and Carmeliet, 2004; Yasuhara et al., 2004).
Specifically, ranibizumab and aflibercept bind to VEGF-A, one
of the five isoforms of the VEGF family and one of the strongest
inducers of vascular permeability (Zachary, 2005). VEGF-A has
been shown to have neuroprotective effects in several in vitro and
in vivo PD models (Storkebaum and Carmeliet, 2004; Ylä-
Herttuala et al., 2007).
In addition, neovascular retinal disease such as AMD and
DME are the most common indications of use for intravitreal
anti-VEGF drugs , and are characterised by retinal
neurodegeneration (de Jong, 2006; Tian et al., 2007) Indeed,
AMD and DME share common biological pathways with
neurodegenerative processes, such as oxidative stress and
inflammation. Persons with DME specifically are at a higher
risk of neurodegeneration, since diabetes and the insulin
resistance that precedes it, are known to be closely linked
biologically to neurodegeneration (Simó and Hernández, 2014).
Other factors supporting the link between intravitreal
ranibizumab and the suspected events identified is the time to
onset. While it was not possible to calculate this for any dementia-
related PTs for ranibizumab or aflibercept, for the ranibizumab-
Parkinson’s disease pair, the mean time to event, which was
estimable for four out of six ICSRs, was 2.3 ± 2.0 years. We
expect patients who developed these events to be treatedMarch 2020 | Volume 11 | Article 315
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onset could be calculated was AMD, which generally requires long-
term treatment. During this period, assuming treatment was in line
with the recommendations of summary of product characteristics,
the number of injections which a patient would have received two
years after initiating intravitreal ranibizumab treatment would range
from 8 to over 10, depending on the therapeutic approach used after
a loading phase, i.e., treat and extend or as needed (Steen et al.,
2005). Long-term use of intravitreal anti-VEGF drugs may have led
to a persistent and prolonged suppression of VEGF levels, which
may have in turn triggered neurodegenerative events in a
population with a high baseline risk of such events. The
combined long-term onset of the suspected neurological events
observed and the expected high cumulative dose to which is patient
is likely exposed may be arguments to support the role of anti-
VEGF drugs in increasing the risk of the two neurodegenerative
diseases under study.
While all of these findings appear to support a potential
increased risk of neurodegeneration with intravitreal anti-VEGF
drug use, it is likely that this risk is relevant mostly to persons who
have a high baseline risk of neurodegeneration (e.g., family history
of Alzheimer’s disease, Parkinson’s disease, uncontrolled diabetes,
etc.) and persons at risk of excessive VEGF inhibition with normal
doses. The clinical benefits of intravitreal anti-VEGF drugs are
significant and any potential risk of neurodegeneration, if confirmed
in large pharmacoepidemiology studies, should be weighed against
the expected benefits of treatment.
The present study has several strengths as well as limitations.
Spontaneous report analysis depends heavily on the completeness
of the data recorded. Although most data for the six ICSRs of
interest was recorded, age, sex, treatment initiation date, causality
assessment, indication of use, and dose were often not available for
other ICSRs. Indeed, the vigiGrade completeness score was
generally low. The ICSRs that make up VigiBase are sent to the
UMC from a variety of sources, which may have varying quality of
reporting. Furthermore, there may also be a variation in national
pharmacovigilance methods to assess causality. To address these
limitations, we evaluated causality using a single algorithm, i.e.,
WHO-UMC system for standardized case causality assessment, to
avoid potentially differential misclassification. While we
hypothesise that the suspected events observed may have been
due to cumulative exposure to anti-VEGF drugs, we cannot be
certain of this since the number of previously administered
injections is not known. Finally, another limitation is that
although we used the narrowest possible SMQ terms, the SMQs
for “Dementia” and “Parkinson-like events” do not refer to
specific, well-classified neurodegenerative diseases. Similarly,
some of the PTs also do not refer to specific neurodegenerative
diseases but rather to symptoms of these diseases. For signal
concerning well-defined PTs (e.g., Alzheimer’s disease and
Parkinson’s disease), we do not have information on whether
the conditions are long-lasting and irreversible, criteria that are
important to correctly identify neurodegenerative diseases.
Findings from the present study must be interpreted in light of
its limitations.Frontiers in Pharmacology | www.frontiersin.org 7Despite the limitations of the data sources used and of the
analyses conducted, the identification of a potential signal
highlights the importance of conducting high-powered
pharmacoepidemiological studies to investigate the association
between neurodegenerative disorders and long-term intravitreal
anti-VEGF use. The importance of such studies is that they can
overcome several of the limitations inherent to analyses of
spontaneous ADR databases, such as potential differential
reporting for specific drugs and underreporting, which may be
high given that neurodegenerative diseases are common among
users of intravitreal anti-VEFG drugs, who are generally elderly.
Another important limitation is the inability to adjust for
confounders and especially, the lack of a denominator. In addition,
pharmacoepidemiological studies conducted using claims databases
and/or electronic medical records can also provide detailed
information on exposure, including the temporal relationship
between the exposure and the event of interest.CONCLUSION
Present findings suggest a potential signal for Parkinson’s disease
related to intravitreal ranibizumab use. The plausibility of these
signals is supported by the biological events downstream of
VEGF inhibition, leading to a reduction in synaptic function
and plasticity, impaired neuron signalling and increased
apoptosis. However, the potential signal identified requires
confirmation by pharmacoepidemiological studies. On the
other hand, should this signal be confirmed, it is important to
weigh anti-VEGF drug risks against their benefits, as these drugs
are very effective in preventing or slowing down blindness
among persons with retinal neovascular disease.DATA AVAILABILITY STATEMENT
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